Immunoglobulins Against Bacteria TRIZ Cases

Recombinant DNA encodes multivalent antibodies that neutralize Neisseria gonorrhoeae and improve treatment of drug-resistant infection.

Monoclonal antibodies block S. aureus coagulase and vWbp from activating prothrombin, preventing fibrin shielding and improving local infection control.

Specific Mycobacterium tuberculosis antigen panels improve antibody-based TB detection in simple lateral flow and ELISA formats with less lab dependence.

Low-temperature processing and probiotic complexation preserve functional sIgA in infant formula to support antiviral immune defense.

Separates Fc-free VH3 antibodies using an alkali-stable Protein A resin that preserves binding through repeated alkaline cleaning cycles.

Specific monoclonal antibodies enable accurate pen-side M. hyopneumoniae detection without the complexity of PCR-based assays.

Antibody-loaded nasal microparticles target allergens in the upper airway to reduce symptoms while limiting lower respiratory exposure.

Recombinant anti-immunocomplex antibodies enable faster, more specific non-competitive detection of cyanobacterial hepatotoxin variants in water.

Highly specific B5 antibodies enable simple ELISA detection of B. mallei infections without difficult isolation or non-specific serology.

Pre-coated magnetic particles capture low pathogen counts, while enzyme-based optical detection speeds food and water screening without enrichment.

Conserved-epitope antibodies address BoNT serotype variability by combining high affinity with broad neutralization.

Combining antibodies with different specificities addresses limited cross-reactivity and neutralizes multiple botulinum neurotoxin serotypes.

Specific peptidoglycan fragments support Borrelia burgdorferi detection across infection stages for Lyme disease diagnosis and monitoring.

Camelid VHH domains target LcrV, YscF, and F1, supporting sensitive field detection with simpler large-scale production.

Targeting conserved IsaA antigen, antibody 1D9 overcomes narrow variant-specific protection to deliver broad coverage against MRSA and MSSA strains.

Antigen-antibody binding enables sensitive Stx2 detection via immunoassays, resolving low concentration limits in complex food matrices.

Peptide mimics replicate protective PI-LPS epitopes to confer immunity without adverse reactions from prior exposure.

A multi-marker diagnostic panel detects antibodies and serotonin levels to identify irritable bowel syndrome.

Optimized variable heavy and light chain CDR amino acid sequences enhance opsonophagocytosis to reduce intracellular Mtb growth.

An antibody binds Fusobacterium nucleatum amyloid-like FadA, blocking virulence and enabling precise disease detection.

Recombinant antibody pairs form a FRET signal upon binding target molecules, enabling rapid optical detection without sample pretreatment.

Segmented DrBphP photosensory modules paired with engineered nanobodies reduce structural complexity while enabling deep tissue penetration.

Monoclonal antibodies targeting RoxP enable specific detection of Cutibacterium species without extended cultivation.

Engineered monoclonal antibody binds Acinetobacter baumannii outer membrane protein OMP22, eliminating cross-reactivity with other Gram-negative bacteria.

A tetanus toxin peptide conjugate directs antigens to antigen-presenting cells via pre-existing serum antibodies.

Segmenting diversity into length and sequence dimensions reduces immunogenicity while maintaining functional binding affinity.

Flexible plasmonic gratings enhance fluorescent intensity by 100-fold, enabling single-molecule biomarker detection without expensive PCR instrumentation.

Modified Staphylococcus aureus protein A domains with inserted amino acids enhance immunoglobulin binding capacity on affinity carriers.

Antibodies neutralize Staphylococcus aureus leukotoxins, bypassing antibiotic resistance mechanisms.

Targeting intracellular Dps protein with a two-antibody sandwich assay resolves low specificity and false positives in Campylobacter detection.

Monoclonal antibodies target capsular polysaccharides to detect Neisseria meningitidis serogroup X in biological samples without culture.

Polyamino acid ligands stabilize Fc domain proteins against ambient temperature degradation, enabling storage without refrigeration infrastructure.

Complete genome sequence of Methanobrevibacter ruminantium enables targeted antibody development against rumen methanogens.

Immunoassays detect antibody binding to bacterial toxins and native antigens, enabling non-invasive differential diagnosis of neuroimmune disorders.

Cross-linked Protein A crystals reduce protein leaching and eliminate support materials in chromatography systems.

Phage display library presents host extracellular proteins on viral surfaces to enable rapid microbial binding detection.

Amino acid mutations in Protein L binding domains enhance alkali stability for chromatography matrix regeneration.

An immunochemical assay uses specific antibodies to detect and quantify Pseudomonas aeruginosa signaling molecules.

Humanized antigen-binding molecules target Porphyromonas gingivalis virulence factors through specific molecular recognition.

Monoclonal antibodies bind the extracellular fibrinogen binding protein on Staphylococcus aureus to block immune evasion mechanisms.

Antibodies target Candida heparin-binding motifs to block microbial adhesion, reducing biofilm formation and infection risk on heparin-coated medical devices.

Immunoreactive antibodies identify mutant HPPD proteins to accelerate transgenic plant selection.

Low-affinity antibody bonds enable free diffusion through respiratory mucus to trap pathogens, reducing required doses while maintaining sterilizing immunity.

Recombinant monoclonal antibodies neutralize Mannheimia haemolytica antigens, reducing bovine respiratory disease incidence and treatment costs.

Administering antigens to fish bearing water vesicles enables repeated antibody collection while keeping the host alive.

Burkholderia polypeptides elicit protective immune responses to bypass antibiotic resistance and reduce mortality rates.

Reactive single-domain antibodies bind botulinum neurotoxin light chain A irreversibly, resolving specificity and potency trade-offs.